相关临床试验
308
59 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1900
已完成
168
54.5%
尚未招募
59
19.2%
招募中
72
23.4%
暂停
2
0.7%
终止
1
0.3%
Unknown
3
1.0%
撤回
2
0.7%
暂无批准数据
- One Genomics, co-founded by Harvard Professor George Church, has announced a strategic research collaboration with Kyoto University's CiRA Foundation to advance precision genome engineering technologies. - The partnership combines One Genomics' proprietary high-precision CRISPR design platform, including its patented "Safeguard" approach, with CiRA Foundation's world-leading expertise in induced pluripotent stem cell manufacturing and regenerative medicine. - The collaboration aims to address critical challenges in conventional genome engineering, including off-target mutations and lack of fine-tuning capabilities that restrict precision and safety in clinical applications. - Together, the companies will develop genome engineering technologies that enable greater precision, controllability, and reliability for cellular and clinical applications in regenerative medicine.
- BostonGene and Kyoto University have announced a research collaboration to develop advanced biological signatures for targeted treatment strategies in esophageal squamous cell carcinoma (ESCC) patients. - The partnership will leverage BostonGene's AI-powered platform to analyze tumor molecular profiles and assess their correlation with response to immune checkpoint inhibitor and chemoradiotherapy combination therapy. - The research builds on the NOBEL Phase II trial led by Dr. Manabu Muto, integrating genomic and transcriptomic profiling to identify immune-related biomarkers for improved patient stratification and clinical trial optimization.
- Japanese scientists have initiated clinical trials for a groundbreaking drug that could enable humans to regrow missing or damaged teeth by targeting the USAG-1 protein. - The therapy works by suppressing USAG-1, a protein that limits tooth growth, with successful preclinical results demonstrated in mice and ferrets. - Initial human trials will test 30 men aged 30-64 missing at least one tooth, with plans to expand to children with congenital tooth absence if proven safe. - Researchers aim to make the treatment available to the general public by 2030, potentially revolutionizing dental care for millions worldwide.
- Elix and LINC have commercialized the world's first AI drug discovery platform incorporating federated learning models trained on data from 16 pharmaceutical companies, addressing the critical data scarcity challenge in AI drug discovery. - The platform leverages over 1 million compounds and 10 million data points through the kMoL federated learning library, enabling collaborative AI model development while preserving confidential pharmaceutical data. - The initiative emerged from Japan's AMED DAIIA project and includes AI models for on/off-target prediction, ADMET prediction, and molecular generation, with several pharmaceutical companies already adopting the Elix Discovery™ platform. - The commercialization represents a significant milestone in pharmaceutical AI, positioning the platform to become the de-facto standard for AI drug discovery in Japan while contributing to enhanced drug development capabilities globally.
- Researchers discovered that phosphodiesterase 3 (PDE3) inhibitors, currently used for heart disease and thrombosis, can stimulate bone growth by enhancing calcium influx into bone cells. - The study demonstrated that cilostazol treatment significantly increased bone outgrowth in cultured bones and body length in young mice over four weeks. - PDE3 inhibitors work by elevating cGMP levels in chondrocytes, amplifying the CNP signaling pathway that drives extracellular matrix synthesis and bone growth. - The findings suggest potential repurposing of existing PDE3 inhibitors for treating skeletal growth disorders like achondroplasia and idiopathic short stature.
- Towa Pharmaceutical and Kyoto University have initiated the final phase of a clinical trial testing bromocriptine, a Parkinson's drug, as a potential treatment for familial Alzheimer's disease using innovative iPS drug discovery methods. - The trial, running until March 2028, will enroll 24 patients with familial Alzheimer's disease caused by specific gene mutations, with preliminary results showing no disease-specific side effects and potential suppression of cognitive decline. - This represents a novel approach to treating early-onset familial Alzheimer's disease, a rare form affecting individuals under 60, for which no cure currently exists despite available symptomatic treatments.
- Japanese study reveals denosumab reduces fracture risk by 45% compared to oral bisphosphonates in dialysis patients over three years, particularly effective for nonvertebral fractures. - Research identifies potential cardiovascular concerns, with denosumab users showing 3.5 times higher risk of acute myocardial infarction compared to bisphosphonate users. - Findings highlight important clinical trade-offs, as denosumab's independence from kidney clearance makes it valuable for dialysis patients, despite FDA's recent boxed warning for severe hypocalcemia risk.
- Japanese researchers are testing a drug aimed at regenerating teeth, with human trials commencing this September. - The drug targets the USAG-1 antibody, which inhibits tooth growth, showing success in animal studies with ferrets and mice. - Initial human trials will involve 30 men aged 30-64, assessing the drug's efficacy and safety via intravenous administration. - If successful, the treatment could be available by 2030, potentially transforming dental care by offering a natural alternative to implants.
- Rege Nephro has successfully raised $22.5 billion yen ($150 million) in Series B funding to advance clinical trials for kidney disease therapies. - The funding will support Phase II trials of RN-014, a retinoic acid receptor agonist, for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and preparations for US trials. - Funds will also facilitate preclinical trials for RN-032, a cell therapy targeting Chronic Kidney Disease (CKD) using nephron progenitor cells. - The investment underscores confidence in Rege Nephro's iPSC-based technology and its potential to address unmet needs in kidney disease treatment.
